Last reviewed · How we verify
NCT05325073
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
Phase 4 trial testing Erythropoietin in Liver Transplant Rejection in 9 participants. Participants enrolled and being followed up; not accepting new ones.
23 May 2023
Quick facts
| Lead sponsor | Northwestern University |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 9 |
| Start date | 18 February 2022 |
| Primary completion | 23 May 2023 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Erythropoietin — full drug profile →
Conditions studied
- Liver Transplant Rejection — all drugs for Liver Transplant Rejection →
Sponsor
Northwestern University
Who can join
Adults 18 to 74, any sex, with Liver Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of the immune system in liver transplantation and its implications for therapeutic interventions.
Chen G, Hu X, Huang Y, Xiang X, et al · · 2023 · cited 10× · PMID 38098611 · DOI 10.1002/mco2.444
Verify or expand the search:
- PubMed search for NCT05325073
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Erythropoietin
Trials testing the same drug.
- NCT06983756 — " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Out · not yet recruiting
- NCT06590155 — Erythropoietin in HIE Neonate · EARLY_PHASE1 · not yet recruiting
- NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
- NCT05395195 — Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial) · Phase 3 · recruiting
- NCT05300477 — Pharmacological Countermeasures for High Altitude · Phase 4 · active not recruiting
Other recruiting trials for Liver Transplant Rejection
Currently open trials in the same condition.
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
- NCT06400771 — Safety of DNP007 in Healthy Subjects · Phase 1 · recruiting
- NCT06153641 — Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients · active not recruiting
Other Northwestern University trials
Trials by the same sponsor.
- NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
- NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
- NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
- NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
- NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05325073 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwestern University
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05325073.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing